Methylphenidate ER

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D226R0013

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has announced a forthcoming solicitation for a national requirements contract to supply Methylphenidate Extended Release (ER) Tablets. This procurement seeks to establish a reliable, long-term source for Methylphenidate ER in 18mg, 27mg, 36mg, and 54mg strengths, packaged in 100-count bottles. The contract is intended to meet the pharmaceutical needs of multiple federal entities, including the Department of War, Department of Veterans Affairs, Indian Health Service, and the Bureau of Prisons, with distribution facilitated through the DLA and VA prime vendor programs. The scope of this acquisition is national, aiming to ensure consistent and timely availability of these critical pharmaceutical products to authorized federal customers. The contract will be structured as a firm-fixed price, requirements-type agreement, featuring a one-year base period with four additional one-year option periods. This arrangement is designed to provide both stability and flexibility in meeting fluctuating demand over the contract lifecycle. Annual usage estimates for each tablet strength will be detailed in the Schedule of Supplies section of the solicitation, enabling offerors to accurately assess production and supply capabilities. This procurement is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with the applicable Product Service Code 6505, reflecting its focus on pharmaceutical products. The acquisition will be conducted as an unrestricted, fully competitive solicitation in accordance with FAR Part 12 procedures for commercial items. All responsible sources are invited to submit proposals, which will be evaluated by the agency. There are no set-aside requirements or restrictions based on business size or socioeconomic status, ensuring broad competition among qualified manufacturers and suppliers. Interested parties should note that the solicitation will be posted on both the DLA Bid Board System (DIBBS) and SAM.gov. Prospective offerors are encouraged to monitor these platforms and set up automated notifications for updates or changes to the solicitation. The anticipated release date for the solicitation is September 2026, though DLA reserves the right to adjust this timeline as necessary. For further information or to address specific questions, interested vendors may contact Jeremy Brown at (445) 737-5419 or via email at [email protected]. Secondary contact is Jason Wray, available at (445) 737-6304 or [email protected]. This opportunity represents a significant and stable source of federal pharmaceutical procurement, suitable for manufacturers with the capacity to meet national requirements for Methylphenidate ER tablets over a multi-year period. Contractors with established capabilities in pharmaceutical preparation manufacturing and distribution are encouraged to review the solicitation upon release and consider participation.